Expression of glomerular epithelial protein 1 (GLEPP1), a receptor tyrosine phosphatase present on the apical cell surface of the glomerular podocyte, and podocyte morphology were investigated in renal specimens from 51 patients with biopsy-diagnosed immunoglobulin A nephropathy (IgAN) and 11 controls. Clinical parameters, such as daily proteinuria were obtained from the patients' records and pathological manifestations of IgAN in the specimens were graded. GLEPP1 was strongly expressed and diffusely distributed in the glomeruli of control specimens. GLEPP1 expression was reduced in IgAN, especially in patients with nephrotic proteinuria and severe pathological manifestations. Podocyte injury was evident in IgAN and was associated with lower GLEPP1 expression and higher pathological grade. GLEPP1 expression was also significantly associated with clinical parameters. The results of this study suggest that GLEPP1 expression may be a useful marker of podocyte injury in IgAN, and may be predictive of clinical and pathological severity.
Introduction
Podocytes, also known as visceral epithelial cells, are a vital component of the glomerular filtration barrier and its sizeselective properties. Podocyte injury has been intensively investigated in nephrotic syndrome caused by focal segmental glomerulosclerosis (FSGS), 1 -3 especially in hereditary forms of steroid-resistant nephrotic syndrome. 4 Structural alteration of podocytes has also been reported in type 2 diabetic nephropathy 5 and minimal change disease (MCD). 6 Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell processes and foot processes in the kidney. This receptor is assumed to play an important role in regulating the structure and function of podocyte foot processes. In a rat model of puromycin aminonucleoside nephrosis, changes in GLEPP1 were found to J Tian, H Ping Wang, Y Ying Mao et al. Reduced GLEPP1 expression and podocyte injury in IgA nephropathy reflect podocyte injury. 7 Clinically, loss and redistribution of GLEPP1 in podocytes may represent a useful phenotypic marker in nephrotic syndrome associated with MCD. 8 As yet, the role of podocyte injury and GLEPP1 expression are undetermined in immunoglobulin A nephropathy (IgAN), the most frequent pathological type of primary nephrosis in China. In this study we investigated the expression of GLEPP1 and podocyte injury in renal specimens from IgAN patients. In addition, the relationship between GLEPP1 expression and clinical manifestations was analysed.
Materials and methods

BIOPSY SPECIMENS
Renal biopsy specimens from patients with biopsy-proven IgAN were studied. Histologically non-affected parts of tumour nephrectomies were used as control specimens.
PATHOLOGICAL GRADING
The tissue was fixed in formalin and embedded in paraffin. 3 µm thick sections were taken and treated with haematoxylin and eosin and Masoon stain. The severity of pathological manifestations were graded according to the system of Lee: 9 grade I, mostly normal glomeruli; grade II, less than half of the glomeruli show localized mesangial proliferation and sclerosis; grade III, diffuse mesangial proliferation and thickening with focal and segmental variation and focal interstitial oedema, and infiltrate occasionally present; grade IV, marked diffuse mesangial proliferation and sclerosis with tubular atrophy and interstitial inflammation; grade V, as grade IV, but more severe.
IMMUNOHISTOCHEMICAL STAINING FOR GLEPP1
An avidin -biotin technique, in which a biotinylated secondary antibody reacts with several peroxidase-conjugated streptavidin molecules, was used to detect GLEPP1 expression. Briefly, control and patients' tissues were embedded in paraffin and 3 µm thick sections were subjected to antigen retrieval in a microwave oven for 12 min. Endogenous peroxidase was blocked using 1% hydrogen peroxide in phosphate buffered saline (PBS); blocking was performed in 10% rabbit serum. Sections were sequentially incubated with the primary antibody (5C11, anti-human GLEPP1, BioGenex, San Ramon, California, USA), the secondary biotinylated antibody and peroxidase-labelled streptavidin. Peroxidase activity was detected using 3,5-diaminobenzidine (Sigma, St Louis, Missouri, USA). The specificity of antibody labelling was demonstrated by the lack of staining after substituting PBS and control immunoglobulins for the primary antibody.
GLEPP1 EXPRESSION SCORE
The expression of GLEPP1 was quantified using computer-assisted image analysis software (KS400 image analysis software version 3.0, Carl Zeiss Vision, Oberkochen, Germany). A region of interest was drawn around a glomerulus showing staining within the colour spectrum specific for diaminobenzidine, as described elsewhere. 10, 11 The fixed intensity threshold was determined based on the control specimens. A score was obtained from multiplying the area affected by the intensity of the staining. Ten glomeruli per slide were chosen at random and the average score was calculated.
TRANSMISSION ELECTRON MICROSCOPY
Fresh renal biopsy specimens were fixed in glutaraldehyde (3.75%, pH 7.2 -7.4) and 40 -60 nm thick sections were cut. The
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ultramicroscopic morphology of the podocytes was observed using a transmission electron microscope. Podocyte injury was defined as the presence of one of the following phenomena: diffusive effacement of foot processes, microvillus transformation, or detachment of the podocyte from the glomerular basement membrane (GBM).
CLINICAL PARAMETERS
Clinical parameters, including daily proteinuria, serum albumin, serum creatinine and creatinine clearance, were obtained from the patients' records.
DATA ANALYSIS
The GLEPP1 scores of IgAN patients were compared with those of controls using a twotailed unpaired Student's t-test. Data were expressed as mean ± SD. The relationship between GLEPP1 expression and clinical parameters was analysed using Spearman's rank correlation. The relationship between GLEPP1 expression and the incidence of podocyte injury was determined using the χ 2 test. A P-value < 0.05 was considered to be statistically significant.
Results
Biopsies from 51 patients with IgAN were included in the study and were compared with 11 control specimens from non-affected parts of tumour nephrectomies.
EXPRESSION AND DISTRIBUTION OF GLEPP1
The expression of GLEPP1 in the control specimens was strong and distributed throughout the whole glomerulus. In the specimens from patients with IgAN, the expression of GLEPP1 was generally decreased and the distribution was uneven, with expression being absent in sclerotic areas. In glomeruli with severe mesangial proliferation and those surrounded by crescents, the expression was low. Representative profiles of GLEPP1 expression in IgAN patients and controls are shown in Fig. 1 .
The GLEPP1 expression score in IgAN patients was significantly lower than that in control specimens (P < 0.001). When the IgAN patients were divided according to the presence of daily proteinuria and pathological severity, the GLEPP1 expression score was particularly reduced in patients with nephrotic proteinuria and a higher pathological grade (Table 1 ).
GLEPP1 EXPRESSION AND CLINICAL PARAMETERS
The GLEPP1 expression score correlated negatively with daily proteinuria and serum creatinine and correlated positively with serum albumin and creatinine clearance ( Table 2 ).
GLEPP1 EXPRESSION, PODOCYTE INJURY AND PATHOLOGICAL SEVERITY
In the control specimens there was no evidence of podocyte injury, whereas morphological podocyte injury was prominent in IgAN, being characterized by effacement of podocyte foot processes and even detachment of podocytes from the GBM (Fig. 2) .
When patients were divided into two groups according to the average GLEPP1 expression score of 6.3, those with a GLEPP1 expression score < 6.3 had a higher incidence of podocyte injury than those with a GLEPP1 expression score > 6.3 (56.3% versus 22.2%, P < 0.05). In addition, in patients with a pathological grade of III -IV, the incidence of podocyte injury was higher than in patients with a pathological grade of I -II (53.8% versus 23.5%, P < 0.05). 
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Discussion
Podocytes are unique cells with a complex cellular organization. They have three structurally and functionally different segments: the cell body, major processes and foot processes. The podocyte is an important component of the glomerular filtration membrane; normally its foot processes are attached to the outer layer of the GBM. The main function of the podocyte is to stabilize glomerular architecture by counteracting distensions of the GBM and to maintain a large filtration surface through the provision of slit diaphragms. 12, 13 IgAN is a common form of progressive glomerular disease characterized by mesangial proliferation and deposition of IgA. Changes in the podocyte and its function-related molecules have been studied in IgAN, 14 -16 but the exact role of the podocyte in IgAN remains undetermined.
Early podocyte injury is manifested as effacement of the foot processes, whereas chronic injury may lead to podocyte detachment from the GBM and loss in the urine 17 . In the present study, foot process effacement and detachment of podocytes from the GBM, indicating podocyte injury and loss, were much more prominent in patients with IgAN. Podocyte injury was also J Tian, H Ping Wang, Y Ying Mao et al. 18 who reported that podocyte loss was associated with increasing disease severity in IgAN and might cause or contribute to the progressive proteinuria, glomerular sclerosis and filtration failure seen in this disease. Another clinical study has shown that podocyte injury correlates with disease severity and provides additional prognostic information in patients with IgAN. 19 The protein GLEPP1 is highly conserved between rabbit, rat, mouse and human. The gene coding for human GLEPP1 is on the short arm of chromosome 12. 20 It is expressed on the apical surface of the podocyte early in development and is present on the apical surface of podocyte foot processes in the mature phenotype. 21 It has been speculated that GLEPP1 plays an important role in regulating podocyte structure and function, 8, 22, 23 but its role in IgAN has not been investigated. The present study demonstrated that GLEPP1 expression was reduced in IgAN compared with control specimens. In addition, the ultramicroscopic morphology of the podocyte was abnormal in IgAN, and there was a close relationship between GLEPP1 expression and the level of podocyte injury. It is suggested that GLEPP1 could serve as a useful marker of podocyte injury in IgAN. This result is particularly interesting since other podocyte-associated molecules, such as nephrin, podocin and CD2-AP, have been reported to be unchanged in IgAN. 24 In addition to the general decrease in GLEPP1 expression in IgAN, the distribution of GLEPP1 was abnormal and uneven. In sclerotic glomeruli, the absence of GLEPP1 staining could be explained by the fact that all the viable cells were destroyed and replaced by fibrosis and scar tissue. However, GLEPP1 expression was also reduced in areas with mesangial proliferation where fibrosis was not evident. This may indicate a relationship between reduced GLEPP1 expression and mesangial proliferation. Mesangial expansion can occur via several mechanisms, and has been shown to occur as a consequence of podocyte injury and loss; podocyte depletion caused by injecting diphtheria toxin into a susceptible transgenic rat led to severe proteinuria, reduced renal function and segmental/ global glomerulosclerosis, 25 as seen in the later stages of IgAN. The close relationship between reduced GLEPP1 expression and mesangial proliferation is important in the pathogenesis of IgAN since mesangial proliferation is the pivotal characteristic of IgAN and the central component of glomerulosclerosis, which will ultimately lead to end-stage renal disease.
Reduced GLEPP1 expression and podocyte injury in IgA nephropathy
In the present study, the reduction in GLEPP1 expression was even more evident in patients with severe proteinuria and a higher pathological grade of IgAN. The association between reduced GLEPP1 expression and clinical severity was also confirmed by the bivariate correlation of the GLEPP1 expression score with clinical parameters such as proteinuria and serum creatinine. The relationship between GLEPP1 expression and clinical parameters or activity has not been previously reported in IgAN; however, in a recent clinical study on FSGS, reduced expression of GLEPP1 was found to be associated with a poor response to steroids. 26 Another study has shown that urinary podocyte loss may be a marker of disease activity in adult patients with IgAN; treatment with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist reduced the level of urinary podocytes. 27 Due to the diversity of therapeutic strategies for IgAN in the Reduced GLEPP1 expression and podocyte injury in IgA nephropathy patients in the present study, it was difficult to analyse associations between podocyte injury, GLEPP1 expression and treatment responsiveness. However, a poor prognosis can be predicted for IgAN patients with low GLEPP1 expression on the basis of its close association with severe clinical manifestations and higher pathological grade, since it is widely accepted that clinical parameters and pathological severity are reliable and independent risk factors for a poor prognosis in IgAN. 28 In conclusion, GLEPP1 expression was decreased in IgAN and its reduction correlated with clinical and pathological severity. GLEPP1 may be a useful marker of podocyte injury in IgAN.
